

The Boston Area Pharmaceutical Toxicology Group (BAPTG)

“Ocular Toxicity and Toxicology”

Fall 2012 Meeting

Thursday, November 1st, 2012

250 Massachusetts Ave., Auditorium
Cambridge, MA

- 8:00-8:45 Registration, bagels, coffee
- 8:45-9:00 **Welcome and introduction**
Page Bouchard, DVM, DACVP – Global Head of Preclinical Safety, Novartis
- 9:00-9:45 **The Ophthalmic Examination in Safety Studies: Procedures, Normals, and Meaningful Findings**
Jay Fortner, DVM, DACLAM – Pfizer
- 9:45-10:30 **Maintaining Clinical Relevance in Ocular Toxicity Studies – Intervening Treatments & Incorporation of Clinical Technologies**
Brenda Smith, PhD – Alcon
- 10:30-11:00 Break
- 11:00-11:45 **Understanding What We Cannot See – The Challenges of the Ocular PK of Biologics**
Mark Milton, PhD – Novartis
- 11:45-1:00 Lunch
- 1:00-1:45 **Ocular Pathology of Ocular Administration of Therapeutic Drugs and Devices**
Ken Schafer, DVM, DACVP – Vet Path Services
- 1:45-2:30 **Preclinical development of antisense oligonucleotides for ocular disease**
Husam Younis, PhD – Isis
- 2:30-3:00 Break
- 3:00-3:45 **MEK-Inhibitor Induced Retinopathy: Mechanistic Insights Acquired Through the Development of a Preclinical Model**
Stan Spence, PhD – Novartis
- 3:45-4:30 **IND-Enabling Studies of EBI-005: A Novel Protein IL-1 Receptor Inhibitor for Topical Treatment of Dry Eye Syndrome**
Eric Furfine, PhD – Eleven Biotherapeutics